Is INmune Bio Stock a Good Investment?
INmune Bio Investment Advice | INMB |
- Examine INmune Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research INmune Bio's leadership team and their track record. Good management can help INmune Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact INmune Bio's business and its evolving consumer preferences.
- Compare INmune Bio's performance and market position to its competitors. Analyze how INmune Bio is positioned in terms of product offerings, innovation, and market share.
- Check if INmune Bio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about INmune Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in INmune Bio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if INmune Bio is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Good | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine INmune Bio Stock
Researching INmune Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 24.0% of the company shares are held by company insiders. The book value of INmune Bio was currently reported as 1.74. The company recorded a loss per share of 2.18. INmune Bio had not issued any dividends in recent years.
To determine if INmune Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding INmune Bio's research are outlined below:
| INmune Bio is way too risky over 90 days horizon | |
| INmune Bio appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 155 K. Net Loss for the year was (30.01 M) with profit before overhead, payroll, taxes, and interest of 42 K. | |
| INmune Bio currently holds about 61.21 M in cash with (11.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41. | |
| Roughly 24.0% of the company shares are held by company insiders |
INmune Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in INmune Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to INmune Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
INmune Bio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 163.16 M.Basic technical analysis of INmune Stock
As of the 20th of March, INmune Bio retains the Market Risk Adjusted Performance of (1.16), risk adjusted performance of 0.1838, and Downside Deviation of 5.19. INmune Bio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.INmune Bio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific INmune Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on INmune Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases INmune Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
INmune Bio's Outstanding Corporate Bonds
INmune Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. INmune Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most INmune bonds can be classified according to their maturity, which is the date when INmune Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45782BAD64 Corp BondUS45782BAD64 | View | |
| Installed Building Products Corp BondUS45780RAA95 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand INmune Bio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing INmune Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1838 | |||
| Market Risk Adjusted Performance | (1.16) | |||
| Mean Deviation | 4.83 | |||
| Semi Deviation | 4.26 | |||
| Downside Deviation | 5.19 | |||
| Coefficient Of Variation | 506.33 | |||
| Standard Deviation | 6.36 | |||
| Variance | 40.49 | |||
| Information Ratio | 0.2077 | |||
| Jensen Alpha | 1.17 | |||
| Total Risk Alpha | 1.78 | |||
| Sortino Ratio | 0.2548 | |||
| Treynor Ratio | (1.17) | |||
| Maximum Drawdown | 28.67 | |||
| Value At Risk | (6.87) | |||
| Potential Upside | 12.97 | |||
| Downside Variance | 26.91 | |||
| Semi Variance | 18.14 | |||
| Expected Short fall | (5.87) | |||
| Skewness | 0.7914 | |||
| Kurtosis | 0.5853 |
| Risk Adjusted Performance | 0.1838 | |||
| Market Risk Adjusted Performance | (1.16) | |||
| Mean Deviation | 4.83 | |||
| Semi Deviation | 4.26 | |||
| Downside Deviation | 5.19 | |||
| Coefficient Of Variation | 506.33 | |||
| Standard Deviation | 6.36 | |||
| Variance | 40.49 | |||
| Information Ratio | 0.2077 | |||
| Jensen Alpha | 1.17 | |||
| Total Risk Alpha | 1.78 | |||
| Sortino Ratio | 0.2548 | |||
| Treynor Ratio | (1.17) | |||
| Maximum Drawdown | 28.67 | |||
| Value At Risk | (6.87) | |||
| Potential Upside | 12.97 | |||
| Downside Variance | 26.91 | |||
| Semi Variance | 18.14 | |||
| Expected Short fall | (5.87) | |||
| Skewness | 0.7914 | |||
| Kurtosis | 0.5853 |
Consider INmune Bio's intraday indicators
INmune Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of INmune Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 20139.56 | |||
| Daily Balance Of Power | (0.36) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 8.27 | |||
| Day Typical Price | 8.22 | |||
| Price Action Indicator | (0.21) | |||
| Period Momentum Indicator | (0.17) | |||
| Relative Strength Index | 50.93 |
INmune Stock media impact
Far too much social signal, news, headlines, and media speculation about INmune Bio that are available to investors today. That information is available publicly through INmune media outlets and privately through word of mouth or via INmune internal channels. However, regardless of the origin, that massive amount of INmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of INmune Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of INmune Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to INmune Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive INmune Bio alpha.
INmune Bio Corporate Management
| Christopher Barnum | Head Neuroscience | Profile | |
| BSc FRCPath | Chief Officer | Profile | |
| Raymond MD | President, CoFounder | Profile | |
| Joshua Esq | General Counsel | Profile | |
| David MBA | Treasurer CFO | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between INmune Bio's value and its price, as these two are different measures arrived at by various means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.